Earnings Releases·Oct 29, 2026, 4:03 PM ET

DexCom — Third Quarter 2026 Earnings Summary

Worldwide revenue grew 11% year-over-year to $1.344 billion, with U.S. revenue up 14% and international revenue up 5%; GAAP operating income increased 420 basis points to $327.2 million, while Non-GAAP operating income rose 270 basis points to $339.5 million.
Fiscal year 2026 guidance was raised, with revenue midpoint increased to $5.20–$5.25 billion (12–13% growth), Non-GAAP operating margin raised to ~24%, and Adjusted EBITDA margin raised to ~32%.
Announced a new share repurchase authorization of up to $1.0 billion, with treasury stock increasing to 39.7 million shares by September 30, 2026.
Advanced strategic product rollout with the U.S. launch of the Dexcom G7 15 Day System and secured first two international regulatory clearances for the extended wear platform.
Published CONNECT trial results in The New England Journal of Medicine for G7 in Type 2 diabetes patients not on insulin and launched the redesigned Stelo experience.